Range Cancer Therapeutics ETF(CNCR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CNCR Range Cancer Therapeutics ETF

交易中 09-02 13:16:38 EDT

9.02

+0.00

0.00%

最高9.02	最低9.02	成交量0.00
今开9.02	昨收9.02	日振幅0.00%
总市值704.29万	流通市值704.29万	总股本78.08万
成交额0.00	换手率0.00%	流通股本78.08万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CNCR","market":"US","secType":"STK","nameCN":"Range Cancer Therapeutics ETF","latestPrice":9.02,"timestamp":1788369398275,"preClose":9.02,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":780814,"shares":780814,"eps":0.38,"marketStatus":"交易中","change":0,"latestTime":"09-02 13:16:38 EDT","open":9.02,"high":9.02,"low":9.02,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0.38,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.02,"sharesOutstanding":780814,"nav":8.9,"aum":6949244.6,"dividendRate":0.000111,"bidAskSpread":0,"volumeRatio":0},"requestUrl":"/m/hq/s/CNCR","defaultTab":"news","newsList":[{"id":"2664800188","title":"诺华：出现死亡病例，暂停自身免疫细胞疗法相关研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2664800188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664800188?lang=zh_cn&edition=full","pubTime":"2026-09-01 12:21","pubTimestamp":1788236460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BJJMRZ35.SGD","LU0070302665.USD","IE00B4R5TH58.HKD","BK4578","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4007","LU0320765489.SGD","IE0009355771.USD","CNCR","LU0208291251.USD","BK4585","MEDX","PPH","SYNB","NVS","WDNA","BK4532","BK4588","LU0211331839.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663267320","title":"拜耳旗下AskBio完成2期心力衰竭基因疗法试验入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2663267320","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663267320?lang=zh_cn&edition=full","pubTime":"2026-08-31 10:28","pubTimestamp":1788143322,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663012684","title":"中国首款血友病基因疗法被退货，天价药支付困局如何破解？","url":"https://stock-news.laohu8.com/highlight/detail?id=2663012684","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663012684?lang=zh_cn&edition=full","pubTime":"2026-08-29 15:25","pubTimestamp":1787988312,"startTime":"0","endTime":"0","summary":"武田与信念医药终止三年合作，上市逾一年仍未开出首张处方。近日，武田中国与信念医药发布联合声明，宣布双方关于血友病B基因疗法波哌达可基注射液（商品名：信玖凝?）的商业化合作已于8月2日正式终止。这意味着，这桩缔结于2023年10月的独家商业化合作，在存续不足三年后宣告终结。据悉，波哌达可基是中国首个获批上市的血友病B基因治疗药物，也是全国首款获批的基因治疗产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608293859274280.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608293859274280.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661244441","title":"【券商聚焦】中信建投：肿瘤mRNA疫苗开创肿瘤治疗新范式，国内企业加速追赶","url":"https://stock-news.laohu8.com/highlight/detail?id=2661244441","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661244441?lang=zh_cn&edition=full","pubTime":"2026-08-24 09:19","pubTimestamp":1787534349,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，随着Moderna个性化肿瘤mRNA疫苗临床III期取得积极结果，mRNA肿瘤疫苗正朝着商业化阶段迈进，市场空间有望逐步打开。mRNA肿瘤疫苗与ICIs联用有望开创肿瘤治疗的新范式。分类来看，个性化肿瘤疫苗具有潜在更优的治疗效果，虽然生产成本较高，但也有更大的定价空间，而通用型疫苗凭规模化生产和较低成本，有望覆盖更广泛的患者群体。AI有望赋能多个环节，加速mRNA肿瘤疫苗的迭代升级。目前国内肿瘤mRNA疫苗研发正加速追赶，未来有望实现差异化突破，相关企业及产业链公司有望受益。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989097","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601066","BK0276","MRNY","CANC","KCE","MRNX","LU0329678170.USD","LU0329678337.USD","LU0737861772.HKD","BK1209","06078","LU2488822045.USD","BK1583","CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661991241","title":"中信建投：肿瘤mRNA疫苗开创肿瘤治疗新范式 国内企业加速追赶","url":"https://stock-news.laohu8.com/highlight/detail?id=2661991241","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661991241?lang=zh_cn&edition=full","pubTime":"2026-08-24 08:26","pubTimestamp":1787531164,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MRNY","MRNX","CANC","CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656875551","title":"FDA授予Xellsmart帕金森病现货型细胞疗法快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2656875551","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656875551?lang=zh_cn&edition=full","pubTime":"2026-08-04 21:07","pubTimestamp":1785848846,"startTime":"0","endTime":"0","summary":"XellSmart专有的现货型iPSC衍生细胞疗法XS411获得美国FDA快速通道资格，标志着其全球临床开发的重要里程碑。　　2026年7月28日，XellSmart宣布，其自主研发的针对帕金森病的同种异体、现货型、可注射iPSC衍生细胞疗法候选产品XS411，已正式获得美国食品药品监督管理局授予的快速通道资格。这一监管认定彰显了美国卫生监管机构对XS411临床价值及其解决帕金森病治疗中重大未满足临床需求潜力的认可，是其全球临床开发和未来市场准入的关键里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-04/doc-inimeknz5555117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["CNCR","LABU","BK4588","WDNA","BK4585","SYNB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://loncarfunds.com/about-cncr/","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.01},{"period":"6month","weight":0.1181},{"period":"1year","weight":0.181},{"period":"ytd","weight":0.1171}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":-0.006537},{"month":2,"riseRate":0.454545,"avgChangeRate":0.008222},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.035928},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.005206},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.002971},{"month":6,"riseRate":0.454545,"avgChangeRate":0.004127},{"month":7,"riseRate":0.636364,"avgChangeRate":0.014964},{"month":8,"riseRate":0.363636,"avgChangeRate":0.002754},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.006126},{"month":10,"riseRate":0.2,"avgChangeRate":-0.060718},{"month":11,"riseRate":0.545455,"avgChangeRate":0.063822},{"month":12,"riseRate":0.090909,"avgChangeRate":-0.039193}],"exchange":"NASDAQ","name":"Range Cancer Therapeutics ETF","nameEN":"Range Cancer Therapeutics ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Range Cancer Therapeutics ETF(CNCR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Range Cancer Therapeutics ETF(CNCR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Range Cancer Therapeutics ETF,CNCR,Range Cancer Therapeutics ETF股票,Range Cancer Therapeutics ETF股票老虎,Range Cancer Therapeutics ETF股票老虎国际,Range Cancer Therapeutics ETF行情,Range Cancer Therapeutics ETF股票行情,Range Cancer Therapeutics ETF股价,Range Cancer Therapeutics ETF股市,Range Cancer Therapeutics ETF股票价格,Range Cancer Therapeutics ETF股票交易,Range Cancer Therapeutics ETF股票购买,Range Cancer Therapeutics ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Range Cancer Therapeutics ETF(CNCR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Range Cancer Therapeutics ETF(CNCR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}